Arduini, Arduino, Bonomini, Mario, Savica, V., Amato, A and Zammit, Victor A.. (2008) Carnitine in metabolic disease : potential for pharmacological intervention. Pharmacology & Therapeutics, Vol.120 (No.2). pp. 149-156. ISSN 0163-7258

Full text not available from this repository.

Abstract

l-carnitine (LC) deficiency is commonly observed in chronic hemodialysis (HD) patients. As a result of this and other causes of secondary LC deficiencies, LC has been described as a “conditionally essential nutrient” or “conditional vitamin”. Although a large number of clinical trials regarding the beneficial effects of LC administration in HD patients have been published, some controversy about its use in this indication persists. In this article, we will review the use of LC in dialysis patients, by focussing mainly on those experimental and clinical data supporting the notion that supra-physiological concentrations of LC in plasma and target organs may exert beneficial effects on several metabolic parameters that have derangements of a common origin (e.g. insulin resistance, type 2 diabetes, dyslipidemia) and which are frequently present in end-stage renal disease (ESRD) patients undergoing dialysis.

Item Type:	Journal Article
Subjects:	R Medicine > R Medicine (General)
Divisions:	Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School
Journal or Publication Title:	Pharmacology & Therapeutics
Publisher:	Elsevier Inc.
ISSN:	0163-7258
Official Date:	November 2008
Dates:	Date Event November 2008 Published
Volume:	Vol.120
Number:	No.2
Page Range:	pp. 149-156
Identification Number:	10.1016/j.pharmthera.2008.08.008
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
URI:	http://wrap.warwick.ac.uk/id/eprint/45273

Request changes or add full text files to a record

Actions (login required)

View Item